An infusion suite is scheduled in chairs. It is paid in codes and minutes.

The RealityThe chair was free. The billing rule was not.

⚠️

The Problem

The schedule and the payment rules disagree.

Chairs and drug run times drive the calendar. Initial codes, access sites and minutes drive the claim. Nobody reconciles them until the remittance arrives.

🔧

The Solution

Build the session around the billable unit.

One initial code per encounter unless there are separate IV sites. Concurrent capped at one. Hydration alongside anything else earns nothing. Encode those in the template, not in somebody’s memory.

✅

The Resolution

A day that bills what it looked like.

Fewer surprises in the remittance file, and a chair plan that reflects how the session is actually paid rather than how long the bag takes.

The infusion billing hierarchy is what actually sets your chair plan

Start with the rule that surprises people most. Per the 2026 NCCI Medicare policy manual, only one initial service code may be reported for a patient encounter unless it is medically reasonable and necessary that the administrations occur at separate intravenous access sites.

Read that again with a schedule in front of you. A patient who receives two different products in one visit does not automatically generate two initial codes. The second one is sequential, not initial, and it pays accordingly, unless there is a documented clinical reason for a second access site. A schedule built on the assumption that each product is its own billable event is going to be wrong about what the day earns.

Two further constraints from the same manual tighten it. Concurrent infusion carries a hard cap of one unit per patient encounter. And hydration running concurrently with another drug administration is not separately reportable at all. There is a related trap worth naming: where the sole purpose of fluid administration is to maintain patency of an access device, the infusion is neither diagnostic nor therapeutic and is not separately reportable.

One caution that matters for neurology specifically. The familiar infusion-over-injection-over-hydration hierarchy is stated in MAC articles for facility coding. The office rule is the one above. Telling a practice manager the facility hierarchy governs their suite is a common and expensive piece of misinformation, and it leads to schedules optimised for a rule that does not apply to them.

Incident to supervision moved, and most infusion policies did not

For years the operating assumption was simple: a physician had to be physically in the office suite while an infusion ran. That is no longer what the regulation says.

42 CFR 410.26 now provides that the presence required for direct supervision may include virtual presence through audio/video real-time communications technology, excluding audio-only. That is a structural change for a practice running infusions at a satellite location or on a day when the prescribing neurologist is at the hospital.

It is not a licence to leave the suite unsupervised, and the exclusion of audio-only is doing real work — a phone call does not satisfy it. But a practice still writing its schedule around a physician being physically present in the same corridor is constraining itself with a rule that changed. Worth checking the policy document before you constrain another quarter of scheduling around it.

Part B versus Part D decides whether the drug is even yours to buy

The buy-and-bill question turns on a single test, and it is more mechanical than most people expect. Medicare guidance defines the term “usually” as more than 50 percent of the time for all Medicare beneficiaries who use the drug, and a drug self-administered by more than half of beneficiaries is excluded from Part B coverage.

For a neurology practice this is the line that separates an infusion suite product from a pharmacy product, and it is why two drugs treating the same condition can sit on opposite sides of the practice’s inventory and cash flow. It is worth having that answer recorded per product in the system rather than rediscovered per patient.

One thing we are deliberately not going to tell you: that Medicare has a rule about white bagging. It does not. We searched CMS, the Federal Register, MedPAC and GAO and found no federal rule on it. White bagging is a commercial-payer and state-law question, and anyone presenting it as a Medicare requirement is wrong. If a payer is mandating it, that is a contract conversation, not a compliance one.

JW and JZ modifiers are where a clean day quietly fails

This one catches practices that have been doing everything else right. Per CMS guidance on discarded drugs, JW is reported for discarded amounts from single-dose containers or single-use packages separately payable under Part B. JZ is required on all claims billing drugs from single-dose containers or single-use packages when there are no discarded amounts.

JZ is the half that gets missed, because it feels like a modifier for nothing. It is not optional. Every single-dose-container claim needs one or the other, and a system that only prompts for JW when waste is recorded will silently omit JZ on every clean administration. That is a claims-edit problem waiting to happen, and it is trivial to fix at the template level.

Worth reading alongside it: an OIG audit issued in May 2025 found that for 42 percent of intravitreal injections in its audit period, providers billed a same-day evaluation and management service using modifier 25, and that documentation did not support the modifier in 22 of 24 sampled services. That audit is about eye injections, not neurology infusion. We are citing it as an enforcement signal about same-day modifier 25 discipline around drug administration generally, not as neurology-specific authority.

Infusion chair utilization follows the clock, not the calendar

The last piece is the one that most directly touches scheduling software. Whether a service is billable at all can turn on elapsed minutes.

A suite scheduled in tidy half-hour blocks cannot see any of that. The system knows when the appointment started and when the next one begins; it does not know when the line opened and closed, which is the fact the claim turns on. Capturing start and stop at the chair, in the record rather than on a paper sheet, is the single change that makes the rest of this enforceable.

That is the real argument for neurology infusion scheduling software setup being treated as a configuration project rather than a purchase. The product will happily schedule chairs. Making it schedule billable units takes a template with start and stop times, a prompt for access site when a second product appears, and a modifier rule that fires on every single-dose container. Our workflow optimization engagements treat this as the same class of work as any other template build.

Where to start

Pull one week of infusion encounters and check three things: how many carried more than one initial code and whether a separate access site was documented, how many single-dose-container lines went out without JW or JZ, and how many sessions have no recorded start and stop time. Those three counts will tell you where the leak is faster than any vendor demonstration.

Then fix the template before you fix the schedule. A schedule built on top of a template that cannot record the billable facts will keep producing days that look full and bill thin. A broader EHR solutions review usually finds the same pattern in the neurology suite that it finds in oncology, for the same reason.

Infusion billing and scheduling: common questions